SciBase Announces Changes to Warrants Following Rights Issue
As an innovative player in the medical technology space, SciBase is taking proactive steps to ensure the value of its warrants reflects the latest capital restructuring. SciBase Holding AB has officially recalibrated the terms of the warrants from series TO 2, which were first issued during a capital raise initiative. This recalculation arises from a recent rights issue, where the company's board executed significant adjustments to enhance its financial strategy.
Details of the Recalculated Warrants
In this new framework, each warrant now allows the holder to subscribe for 1.09 shares, with a revised subscription price set at SEK 0.38 per share. These changes are pertinent as they will be effective for the period extending from April 3, 2029, until April 17, 2029. Such adjustments aim to align the warrants with the evolving market conditions and to reflect the rights issue approved on December 29, 2025.
Implications of the Rights Issue
The decision made by SciBase’s board to conduct a rights issue signifies a strategic move to strengthen its financial position. This issue aims to attract further investors and provide existing shareholders with the opportunity to increase their stake in the company while paving the way for future investments and developments. By recalibrating the warrants, SciBase is ensuring that the value and potential of these securities correspond with the changed capital landscape.
Results of the TO 2 Offer
Interestingly, a recent announcement revealed that the TO 2 Offer yielded substantial uptake, with around 83.9 percent of all outstanding warrants being accepted. This level of participation indicates a strong confidence among shareholders and holders of warrants, signifying their trust in SciBase's vision and growth trajectory. This response allows the company to potentially gather approximately SEK 33.3 million upon full execution of the options, which in turn will bolster its financial resources for innovation and expansion.
Future Trading Considerations
As a part of these adjustments, the last day for trading in the subscription shares linked to the rights issue has been identified as February 9, 2026. Following this date, an important conversion process will take place, where the newly issued shares from the rights issue and the TO 2 offer will be exchanged on February 16, 2026.
Enhancing Shareholder Value
By undertaking these measures, SciBase aims to not only serve its current shareholders but also attract new investors through enhanced shareholder value and clear communication of its financial strategies. Such moves are crucial for fostering trust and ensuring that all stakeholders benefit from the company’s growth and development.
About SciBase and Its Vision
SciBase is recognized as a global leader in medical technology, focusing on early detection and prevention within dermatology. Through its pioneering technology and commitment to integrating AI with advanced diagnostic methods, SciBase is positioned to significantly impact skin health management and improve patient outcomes.
The company has remained dedicated to its primary ethos: to minimize patient suffering through timely interventions, enhancing clinical practices, and ultimately reducing healthcare expenditures. Established on substantial research at the renowned Karolinska Institute, SciBase exemplifies innovation in dermatological medicine.
Investment Opportunities and Advantages
Since its listing on the Nasdaq First North Growth Market in 2015, SciBase has drawn a robust investor base. The comprehensive support from its Certified Advisor, DNB Carnegie Investment Bank AB, ensures that the company remains on the right track as it navigates the evolving market landscape.
Frequently Asked Questions
What are the main changes to the warrants of series TO 2?
Each warrant now entitles the holder to subscribe for 1.09 shares at a subscription price of SEK 0.38.
What is the last day of trading for the rights issue shares?
The last day for trading in these shares is February 9, 2026.
How much capital is SciBase expected to gain from the TO 2 Offer?
SciBase could raise approximately SEK 33.3 million upon full exercise of the warrants.
What is the duration for which the warrants can be exercised?
The warrants can be exercised from April 3, 2029, to April 17, 2029.
What is SciBase's primary focus as a company?
SciBase specializes in the early detection and prevention of skin-related issues using advanced technology and AI methods.
